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Abstract 
Purpose: To study whether B7-H3 and B7-H4 proteins can be candidate drug targets for preventing 
and treating hepatoma. 
Methods: Western blot assay was used to study the expressions of B7-H3 and B7-H4 proteins and the 
effect of sorafenib on their expressions in different human hepatoma cell lines (HepG2, Hep3B, BEL-
7402, BEL-7404, BEL-7405, QGY-7701, QGY-7703, SMMC-7721, MHCC97H, MHCC97L, HCCLM3 
and HCCLM6). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to 
study the cytotoxicity of sorafenib against different human hepatoma cell lines. 
Results: The expressions of B7-H3 (0.26 - 0.84 μM) and B7-H4 (0.18 - 0.78 μM) proteins in different 
human hepatoma cell lines were significantly (p < 0.01) up-regulated, compared with that of the normal 
human liver cell line (HL-7702) (0.09 and 0.08 μM). Sorafenib was cytotoxic on Hep3B, BEL-7404, 
MHCC97H, HCCLM3 and HCCLM6 cells with half-maximal inhibitory concentration (IC50) of 14.56, 9.14, 
9.46, 17.21 and 9.29 μM, respectively. After treatment with sorafenib at concentrations of 5, 10 and 20 
μM, the expressions of B7-H3 protein in MHCC97H, HCCLM3 and HCCLM6 cells and the expressions 
of B7-H4 protein in Hep3B, BEL-7404 and MHCC97H cells were significantly (p < 0.01) down-regulated, 
compared with that of the control. 
Conclusion: Over-expression of B7-H3 and B7-H4 proteins is common in different human hepatoma 
cell lines and thus, B7-H3 and B7-H4 proteins may be regarded as candidate drug targets for preventing 
and treating hepatoma. 
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Primary hepatoma is the 15th most common 
cancer and the 2nd leading cause of cancer 
mortality worldwide [1]. Primary hepatoma 
remains the 8th most common malignancy in 
women and the 5th in men according to the 
estimates of incidence of cancer in 2000 [2]. 
There were 749 thousand new cases and 695 
thousand deaths from hepatoma in 2008 [3]. 
Therefore, finding novel therapeutic methods are 
urgent for preventing and treating hepatoma. 
 
Nowadays, the therapeutic strategies of 
hepatoma include surgical resection [4], 
biotherapy [5], interventional therapy [6], 
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radiotherapy [7], chemotherapy [8], Chinese 
medicinal therapy [9] etc. The B7 protein family 
including B7-2, B7-1, B7-H4, B7-H3, B7-H2 and 
B7-H1 is a group of co-stimulators, which is 
related to the activation of T and B cells and 
immunologic functions. Therefore, the B7 protein 
family is widely applied to treat autoimmune 
diseases, transplantation immune diseases and 
cancers [10,11]. 
 
In the present study, western blot was used to 
study the expressions of B7-H3 and B7-H4 
proteins in different human hepatoma cell lines 
(HepG2, Hep3B, BEL-7402, BEL-7404, BEL-
7405, QGY-7701, QGY-7703, SMMC-7721, 
MHCC97H, MHCC97L, HCCLM3 and HCCLM6) 
and normal human liver cell line (HL-7702) [12]. 
Then 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was 
used to study the cytotoxicity of sorafenib against 
these cell lines (Hep3B, BEL-7404, MHCC97H, 
HCCLM3 and HCCLM6), which had the higher 
expressions of B7-H3 and B7-H4 proteins than 
other cell lines. Subsequently, the effects of 
sorafenib on the expressions of B7-H3 and B7-
H4 proteins in Hep3B, BEL-7404, MHCC97H, 
HCCLM3 and HCCLM6 cells were studied using 
Western blot assays. The purpose was to 
determine whether the over-expressions of B7-
H3 and B7-H4 proteins was common in human 
hepatoma cell lines, and B7-H3 and B7-H4 
proteins could be regarded as candidate drug 




Chemicals and reagents 
 
A defined fetal bovine serum, RPMI-1640 and 
DMEM medium were provided by Hyclone 
(Logan, Utah, USA) and Invitrogen (Carlsbad, 
CA, USA). Dimethylsulfoxide (DMSO), primary 
antibodies against β-actin, B7-H3, B7-H4 and 
horseradish peroxidase (HRP)-conjugated 
secondary antibody were purchased from Sigma-
Aldrich (Taufkirchen, Germany). Sorafenib was 
purchased from LKT Labratories (St Paul, 
Minnesota, USA). Enhanced BCA Protein Assay 




The HepG2, Hep3B, BEL-7402, BEL-7404, BEL-
7405, QGY-7701, QGY-7703, SMMC-7721, 
MHCC97H, MHCC97L, HCCLM3, HCCLM6 and 
HL-7702 cells were provided by American Type 
Culture Collection (ATCC, Manassas, VA, USA). 
All cells were separately cultured in RPMI-1640 
or DMEM medium supplemented with 10 % 
defined fetal bovine serum, 100 U/mL of penicillin 
and 100 U/mL of streptomycin at 37 °C in 5 % 




MTT assay was used to evaluate the anti-
proliferative activities of sorafenib against 
Hep3B, BEL-7404, MHCC97H, HCCLM3 and 
HCCLM6 cells. Different human hepatoma cells 
were separately seeded on 96 well plates for 24 
h, and then cells were treated with sorafenib at 
the concentrations of 0 (for control), 1.25, 2.5, 5, 
10, 15, 20 and 40 μM. After 48 h, the MTT was 
added into each well and the cells were cultured 
for another 3 h. Then the DMSO was added into 
each well and the optical density (OD) of the 
DMSO solution was measured at 570 nm using a 
microplate reader (Perkin-Elmer, USA) [13]. The 
inhibition rate of sorafenib against different 
human hepatoma cells were calculated as in Eq 
1 [14]. 
 
Inhibition (%) = {(Ac – As)/Ac}100 ………….. (1) 
 
where Ac and As are the absorbance of control 
and sorafenib samples, respectively. 
 
Western blot assay 
 
The total proteins of untreated HepG2, Hep3B, 
BEL-7402, BEL-7404, BEL-7405, QGY-7701, 
QGY-7703, SMMC-7721, MHCC97H, MHCC97L, 
HCCLM3, HCCLM6 and HL-7702 cells were 
extracted. After treatment with sorafenib at 
concentrations of 0 (for control), 5, 10 and 20 μM 
for 48 h, the total proteins of Hep3B, BEL-7404, 
MHCC97H, HCCLM3 and HCCLM6 were 
extracted. According to the manufacturer’s 
instruction, the concentrations of total proteins 
were determined using an Enhanced BCA 
Protein Assay kit [15]. Then, equal amounts of 
total proteins (about 30 μg) were separated by 
12 % SDS/PAGE and moved onto PVDF 
membrane. After blocking with 5 % fat-free milk, 
the PVDF membranes were incubated with 
primary antibodies against β-actin, B7-H3, B7-H4 
overnight at 4 °C and subsequently with goat 
anti-rabbit/HRP at room temperature for 2 h [16]. 
Finally, all proteins were detected by 
chemiluminescence. An antibody directed 





All data are presented as mean ± standard 
deviation. A one-way ANOVA was used to 
analyze the differences among different groups 
using Dunnett test on SPSS 19.0. When p-value 
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Over-expressions of B7-H3 and B7-H4 
proteins  
 
Western blot was used to study the expressions 
of B7-H3 and B7-H4 proteins in HepG2, Hep3B, 
BEL-7402, BEL-7404, BEL-7405, QGY-7701, 
QGY-7703, SMMC-7721, MHCC97H, MHCC97L, 
HCCLM3, HCCLM6 and HL-7702 cell lines. As 
shown in Figure 1, the expressions of B7-H3 
(0.26 - 0.84 μM) and B7-H4 (0.18 - 0.78 μM) 
proteins in all the hepatoma cell lines were 
significantly (p < 0.01) up-regulated, compared 
with that of the normal human liver cell line (HL-
7702) (0.09 and 0.08 μM). 
 
Cytotoxicity of sorafenib against different 
human hepatoma cell lines 
 
The cell lines (Hep3B, BEL-7404, MHCC97H, 
HCCLM3 and HCCLM6), which had the higher 
expressions of B7-H3 and B7-H4 proteins than 
other cell lines, were used to study the effect of 
sorafenib on the expressions of B7-H3 and B7-
H4 proteins. However, before beginning the 
study, MTT assay was first used to determine the 
cytotoxicity of sorafenib against these cell lines to 
ensure the effectiveness of the drug. As depicted 
in Figure 2, sorafenib was cytotoxic to Hep3B, 
BEL-7404, MHCC97H, HCCLM3 and HCCLM6 
with half maximal inhibitory concentration (IC50) 
values of 14.56, 9.14, 9.46, 17.21 and 9.29 μM, 
respectively. 
 
Inhibitory effects of sorafenib on the 
expressions of B7-H3 and B7-H4 proteins  
 
The effects of sorafenib on the expressions of 
B7-H3 protein in MHCC97H, HCCLM3 and 
HCCLM6 cells and the expressions of B7-H4 
protein in Hep3B, BEL-7404 and MHCC97H cells 
were studied using western blot. As shown in 
Figure 3, after treatment with sorafenib at the 
concentrations of 5, 10 and 20 μM for 48 h, the 
expressions of B7-H3 protein in MHCC97H, 
HCCLM3 and HCCLM6 cells were significantly (p 
< 0.01) down-regulated, compared with that of 
the control. As shown in Figure 4, after treatment 
with sorafenib at the concentrations of 5, 10 and 
20 μM for 48 h, the expressions of B7-H4 protein 
in Hep3B, BEL-7404 and MHCC97H cells were 
significantly (p < 0.01) down-regulated, 




Figure 1: Over-expressions of B7-H3 and B7-H4 proteins in different human hepatoma cell lines (HepG2, 
Hep3B, BEL-7402, BEL-7404, BEL-7405, QGY-7701, QGY-7703, SMMC-7721, MHCC97H, MHCC97L, 
HCCLM3 and HCCLM6), **p < 0.01, compared with that of the normal human liver cell line (HL-7702) 
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Figure 2: Cytotoxicity of sorafenib against Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6 cells 
 
 
Figure 3: Inhibitory effects of sorafenib on the expressions of B7-H3 protein in MHCC97H, HCCLM3 and 
HCCLM6 cells, **p < 0.01, compared with that of the control 
 
 
Figure 4: Inhibitory effects of sorafenib on the expressions of B7-H4 protein in Hep3B, BEL-7404 and MHCC97H 
cells, **p < 0.01, compared with that of the control 
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In the present study, we studied the expressions 
of B7-H3 and B7-H4 proteins in different human 
hepatoma cell lines (HepG2, Hep3B, BEL-7402, 
BEL-7404, BEL-7405, QGY-7701, QGY-7703, 
SMMC-7721, MHCC97H, MHCC97L, HCCLM3 
and HCCLM6) and normal human liver cell line 
(HL-7702) using western blot assay. Then, the 
cytotoxicity of sorafenib against Hep3B, BEL-
7404, MHCC97H, HCCLM3 and HCCLM6 cells 
and the effect of sorafenib on the expressions of 
B7-H3 and B7-H4 proteins in these cells were 
studied using MTT and western blot assays. 
 
Defect in the immune response may lead to the 
growth of tumor. T cell plays an important role in 
immune response. Co-stimulatory ligands such 
as CD80 and CD86 play an important role in the 
startup and maintenance of immune response, 
and their non-expressions in tumor cells has 
been regarded as a reason for immune evasion 
[17,18].  
 
The expressions of inhibitory cofactors such as 
CD152 and PD-1 in immune cells, and the 
expression of their ligands in tumor cells are 
related to tumor pathogenesis [19]. Nowadays, 
inhibiting the interaction of inhibitory cofactors 
with their ligands has been successfully used to 
treat tumor [20]. Blocking the expressions of 
inhibitory cofactors in immune cells and the 
expressions of their ligands in tumor cells may be 
important in suppressing the immune evasion of 
tumor cells [21]. 
 
B7-H4 and B7-H3 are two major co-stimulators 
or ligands of inhibitory cofactors in B7 protein 
family, which is related to the activation of T cells 
and immunologic functions [22]. B7-H4 is 
expressed at the transcriptional level in the 
thymus, lung and spleen [23] while B7-H3 is 
widely expressed at the transcriptional level in 
lymphoid organs, liver, testis, uterus, lung, 
skeletal muscle, etc [24]. Therefore, B7-H4 and 
B7-H3 seem to be limited at the translational 
level [25]. It was reported that the B7-H4 and B7-
H3 proteins were expressed in non-small-cell 
lung cancer [26].  
 
Some studies indicate that B7-H4 is over-
expressed at the transcriptional level in human 
hepatoma cell line BEL-7404 [27]. However, the 
expressions of B7-H3 and B7-H4 proteins in 
different human hepatoma and normal human 
liver cell lines and the effect of sorafenib on their 
expressions were still unknown. Because 
sorafenib can prevent both tumor cell 
proliferation and angiogenesis, and has been 
successfully used to treat hepatoma [28,29], it 
was considered as positive drug in the present 
study. 
 
The results indicate that the expressions of B7-
H3 and B7-H4 proteins in all the human 
hepatoma cell lines were significantly up-
regulated, compared with that of the normal 
human liver cell line (HL-7702). Sorafenib was 
cytotoxic to Hep3B, BEL-7404, MHCC97H, 
HCCLM3 and HCCLM6 with IC50 values of 14.56, 
9.14, 9.46, 17.21 and 9.29 μM, respectively.  
 
After treatment with sorafenib, the expression of 
B7-H3 protein in MHCC97H, HCCLM3 and 
HCCLM6 cells and the expression of B7-H4 
proteins in Hep3B, BEL-7404 and MHCC97H 
cells were significantly down-regulated, 
compared with that of the control. Although over-
expression of B7-H3 and B7-H4 proteins was 
observed in the human hepatoma cell lines, 
expressions of B7-H3 and B7-H4 proteins in liver 
cancer tissues, the relationship between them, 
and the classification of liver cancer requires 




Over-expression of B7-H3 and B7-H4 proteins in 
human hepatoma cell lines are common. 
Sorafenib is cytotoxic to human hepatoma cell 
lines and inhibit t over-expression of B7-H3 and 
B7-H4 proteins in human hepatoma cell lines. 
These findings indicate that B7-H3 and B7-H4 
proteins may be regarded as candidate drug 
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